The authors retrospectively analyzed clinical records to determine the
safety and complication rate of percutaneous ethanol ablation therapy
with more than 10 mL of ethanol administered per session for treatmen
t of malignant hepatic tumors. Ten patients underwent a total of 35 se
ssions with 10 mL or more of ethanol, and four underwent 18 sessions w
ith 10 mL or less. No serious complications occurred with any dose. Pa
in and fever were the most common complications at all doses, and the
higher frequency of these at larger ethanol volumes may be related to
the greater degree of tumor necrosis induced by the larger volume.